6062.T
6062.T operates in the healthcare sector, specializing in biotechnology and providing healthcare facilities and services.
Business. 6062.T operates in the healthcare sector, specializing in biotechnology and providing healthcare facilities and services.
Analyst recommendations
1 analysts · consensus BuyAt a glance
What drives this business
The watch-list the newsroom runs for this company — derived from its sector path, sharpened layer by layer. Not investment advice.
News & coverage
0Sector rotation
Developing storylines
Analysis
AI analysisOpportunity
Upcoming catalysts
Scheduled public events. Informational only — not investment advice.
- Macro
- Rate decisionBank of England rate decision (press conf.)2026-08-06 · GB
- Rate decisionReserve Bank of Australia rate decision (press conf.)2026-08-12 · AU
- Rate decisionNorges Bank rate decision (press conf.)2026-08-20 · NO
- Rate decisionSveriges Riksbank rate decision (press conf.)2026-09-03 · SE
- Rate decisionBank of Canada rate decision (press conf.)2026-09-09 · CA
- Rate decisionEuropean Central Bank rate decision (press conf.)2026-09-10 · EU
- Macro & political
- ElectionSE Swedish Election2026-09-14 · SE
- ElectionUS U.S. Midterms2026-11-03 · US
- ElectionFR French Legislative2027-06-01 · FR
Pre-earnings brief
Signals & dispatch
Composite-score breakdown
Synthesis
6062.T operates in the healthcare sector, specializing in biotechnology and providing healthcare facilities and services.
The company's capital structure is characterized by a debt-to-equity ratio of 0.65, indicating a moderate reliance on debt financing. Its liquidity position is assessed as medium, with a current ratio of 0.93, suggesting limited short-term liquidity cushion. The company reported negative free cash flow of -1.686 billion JPY, driven by capital expenditures of -4.841 billion JPY, which outpaced operating cash flow of 3.732 billion JPY. This highlights a potential strain on liquidity in the near term.
Profitability metrics show a return on equity of 14.2% and a return on assets of 5.6%, which are strong relative to the industry's typical performance. The company's operating income of 4.038 billion JPY and net income of 2.936 billion JPY reflect a healthy margin, although gross profit of 7.244 billion JPY suggests room for improvement in cost management.
The company's revenue is concentrated in a single business segment, with no disclosed geographic diversification. This lack of diversification increases exposure to regional economic and regulatory risks. The absence of segment-specific data limits the ability to assess the performance of individual business lines.
The company's growth trajectory is uncertain, with no specific revenue growth projections provided. However, the negative free cash flow and high capital expenditures suggest a focus on expansion or investment in new projects. The company's operating cash flow of 3.732 billion JPY indicates a positive cash flow from operations, which could support future growth initiatives.
Risk factors include a medium liquidity risk, as the company's cash and equivalents of 9.149 billion JPY are insufficient to cover total debt of 13.452 billion JPY. The risk assessment also notes a low dilution potential, with no significant dilution expected in the near term. The company's capital structure and liquidity position suggest a need for careful management of debt and cash flow to maintain financial stability.
Recent events include analyst estimates that are uniformly set at 1,710.00 JPY, with a mean recommendation of 2.00, indicating a neutral stance. The lack of strong buy or hold recommendations suggests a cautious outlook from analysts. No recent filings or transcripts were provided to assess management commentary or strategic direction.
- The company has a strong return on equity of 14.2%, indicating effective use of shareholder capital.
- The company's liquidity position is medium, with a current ratio of 0.93, suggesting limited short-term liquidity cushion.
- The company's capital expenditures of -4.841 billion JPY outpaced operating cash flow, leading to negative free cash flow.
- The company's revenue is concentrated in a single business segment, increasing exposure to regional economic and regulatory risks.
- Analysts have a neutral stance on the company, with a mean recommendation of 2.00 and a uniform price target of 1,710.00 JPY.
Bull / Bear case
analysis pipelineIn focus — financials by report
Valuation
Revenue by segment
Business relationships
Supply chain
Peer comparison
Market position
Stress test
Predictor forecast
| Metric | Our forecast | Guidance | Consensus |
|---|---|---|---|
| EPS | —no estimate | —no estimate | 105,85 |
| Revenue | —no estimate | —no estimate | 49,0B JPY |
| Operating income | —no estimate | —no estimate | —no estimate |
Options
Short squeeze
Earnings-call key lines
Consensus distribution
sell-side coverageEstimate revisions
consensus EPS · 26-week trendSell-side observations
Themes
ESG
Risk factors
- Net cash is negative after subtracting total debt.
Benchmarks vs cohort
Corporate actions / M&A
FX exposure
Comparable transactions
Derivatives & instruments
Actions
Ask Handelsavisen
- Market data
- Market data cache
- Issuer disclosures
- Public news
- Earnings transcripts
- Consensus estimates
- ESG data
- Dilution Ratio(shares_outstanding_diluted - shares_outstanding_basic) / shares_outstanding_basic
- Net Cashcash_and_equivalents + short_term_investments - short_term_debt - long_term_debt
- Capex To Revenuecapital_expenditure / revenue
- Return On Equitynet_income / total_equity
- Debt To Equity(short_term_debt + long_term_debt) / total_equity
- Cash Conversion Ratiooperating_cash_flow / net_income
- 6062.T Market data — financials · 2026-05-27
- Charm Care Corp Market data — analyst estimates · 2026-05-27